ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
immunoglobulin G1-kappa, anti-[Homo sapiensinterleukin 6 (IL6,IL-6)], chimeric monoclonal antibody;gamma1 heavy chain (1-449)[Mus musculusVH (IGHV5-9-4*01-(IGHD)-IGHJ4*01)[8.8.12](1-119)-Homo sapiensIGHG1*01 (120-449)], (222-213')-disulfide with kappa lig (WHO)
- Siltuximabum (Latin)
- Siltuximab (German)
- Siltuximab (French)
- Siltuximab (Spanish)
- Siltuximab (OS: USAN)
- UNII-T4H8FMA7IM (IS)
Janssen, Finland; Janssen, Ireland; Janssen, Sweden; Janssen Biotech, United States; Janssen-Cilag, Switzerland; Janssen-Cilag, Germany; Janssen-Cilag, Denmark; Janssen-Cilag, United Kingdom; Janssen-Cilag, Greece; Janssen-Cilag, Poland; Janssen-Cilag International, Austria; Janssen-Cilag International NV, Slovenia; Johnson & Johnson, Croatia (Hrvatska)
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.